At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
In Brief
A Phase 4 clinical trial evaluating Rocuronium, Neostigmine, and 2 other interventions for Surgery and Coronary Artery Disease. Completed, enrolled 84 participants across 1 site.
Detailed Summary
The purpose of this study is to examine whether the use of Sugammadex will reduce time from reversal to extubation and improve other post extubation outcomes in Coronary artery bypass grafting patients. This study is a prospective, clinical interventional, randomized single blinded single-center design. The nurses in the cardiac intensive care unit will be blinded to treatment allocation (Group 1 or 2).
Study Details
Timeline
Interventions
Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
Reversal with Sugammadex (2mg/kg)